118 related articles for article (PubMed ID: 17090740)
1. Prasterone.
Kocis P
Am J Health Syst Pharm; 2006 Nov; 63(22):2201-10. PubMed ID: 17090740
[TBL] [Abstract][Full Text] [Related]
2. Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy.
Sánchez-Guerrero J; Fragoso-Loyo HE; Neuwelt CM; Wallace DJ; Ginzler EM; Sherrer YR; McIlwain HH; Freeman PG; Aranow C; Petri MA; Deodhar AA; Blanton E; Manzi S; Kavanaugh A; Lisse JR; Ramsey-Goldman R; McKay JD; Kivitz AJ; Mease PJ; Winkler AE; Kahl LE; Lee AH; Furie RA; Strand CV; Lou L; Ahmed M; Quarles B; Schwartz KE
J Rheumatol; 2008 Aug; 35(8):1567-75. PubMed ID: 18634158
[TBL] [Abstract][Full Text] [Related]
3. Effects of prasterone on bone mineral density in women with systemic lupus erythematosus receiving chronic glucocorticoid therapy.
Mease PJ; Ginzler EM; Gluck OS; Schiff M; Goldman A; Greenwald M; Cohen S; Egan R; Quarles BJ; Schwartz KE
J Rheumatol; 2005 Apr; 32(4):616-21. PubMed ID: 15801015
[TBL] [Abstract][Full Text] [Related]
4. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus.
Petri MA; Mease PJ; Merrill JT; Lahita RG; Iannini MJ; Yocum DE; Ginzler EM; Katz RS; Gluck OS; Genovese MC; Van Vollenhoven R; Kalunian KC; Manzi S; Greenwald MW; Buyon JP; Olsen NJ; Schiff MH; Kavanaugh AF; Caldwell JR; Ramsey-Goldman R; St Clair EW; Goldman AL; Egan RM; Polisson RP; Moder KG; Rothfield NF; Spencer RT; Hobbs K; Fessler BJ; Calabrese LH; Moreland LW; Cohen SB; Quarles BJ; Strand V; Gurwith M; Schwartz KE
Arthritis Rheum; 2004 Sep; 50(9):2858-68. PubMed ID: 15452837
[TBL] [Abstract][Full Text] [Related]
5. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial.
Petri MA; Lahita RG; Van Vollenhoven RF; Merrill JT; Schiff M; Ginzler EM; Strand V; Kunz A; Gorelick KJ; Schwartz KE;
Arthritis Rheum; 2002 Jul; 46(7):1820-9. PubMed ID: 12124866
[TBL] [Abstract][Full Text] [Related]
6. Effects of oral prasterone (dehydroepiandrosterone) on single-dose pharmacokinetics of oral prednisone and cortisol suppression in normal women.
Meno-Tetang GM; Blum RA; Schwartz KE; Jusko WJ
J Clin Pharmacol; 2001 Nov; 41(11):1195-205. PubMed ID: 11697752
[TBL] [Abstract][Full Text] [Related]
7. Prasterone and bone mineral density in women with systemic lupus erythematosus.
Alexander T; Friel PN; Wright JV
J Rheumatol; 2005 Dec; 32(12):2497; author reply 2497-8. PubMed ID: 16331796
[No Abstract] [Full Text] [Related]
8. Effects of prasterone (dehydroepiandrosterone) on markers of cardiovascular risk and bone turnover in premenopausal women with systemic lupus erythematosus: a pilot study.
Marder W; Somers EC; Kaplan MJ; Anderson MR; Lewis EE; McCune WJ
Lupus; 2010 Sep; 19(10):1229-36. PubMed ID: 20530522
[TBL] [Abstract][Full Text] [Related]
9. Effects of dehydroepiandrosterone on bone mineral density: what implications for therapy?
Villareal DT
Treat Endocrinol; 2002; 1(6):349-57. PubMed ID: 15832488
[TBL] [Abstract][Full Text] [Related]
10. Dehydroepiandrosterone for the treatment of systemic lupus erythematosus.
van Vollenhoven RF
Expert Opin Pharmacother; 2002 Jan; 3(1):23-31. PubMed ID: 11772330
[TBL] [Abstract][Full Text] [Related]
11. The effect of dehydroepiandrosterone on lumbar spine bone mineral density in patients with quiescent systemic lupus erythematosus.
Hartkamp A; Geenen R; Godaert GL; Bijl M; Bijlsma JW; Derksen RH
Arthritis Rheum; 2004 Nov; 50(11):3591-5. PubMed ID: 15529389
[TBL] [Abstract][Full Text] [Related]
12. Dehydroepiandrosterone in systemic lupus erythematosus: relationship between dosage, serum levels, and clinical response.
Barry NN; McGuire JL; van Vollenhoven RF
J Rheumatol; 1998 Dec; 25(12):2352-6. PubMed ID: 9858429
[TBL] [Abstract][Full Text] [Related]
13. Prasterone: A Review in Vulvovaginal Atrophy.
Heo YA
Drugs Aging; 2019 Aug; 36(8):781-788. PubMed ID: 31290076
[TBL] [Abstract][Full Text] [Related]
14. A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus.
van Vollenhoven RF; Park JL; Genovese MC; West JP; McGuire JL
Lupus; 1999; 8(3):181-7. PubMed ID: 10342710
[TBL] [Abstract][Full Text] [Related]
15. GL-701 Genelabs.
Norman P
Curr Opin Investig Drugs; 2001 Feb; 2(2):231-6. PubMed ID: 11816836
[TBL] [Abstract][Full Text] [Related]
16. Comparison of intravaginal 6.5mg (0.50%) prasterone, 0.3mg conjugated estrogens and 10μg estradiol on symptoms of vulvovaginal atrophy.
Archer DF; Labrie F; Montesino M; Martel C
J Steroid Biochem Mol Biol; 2017 Nov; 174():1-8. PubMed ID: 28323042
[TBL] [Abstract][Full Text] [Related]
17. Effects of dehydroepiandrosterone supplement on health-related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus.
Nordmark G; Bengtsson C; Larsson A; Karlsson FA; Sturfelt G; Rönnblom L
Autoimmunity; 2005 Nov; 38(7):531-40. PubMed ID: 16373258
[TBL] [Abstract][Full Text] [Related]
18. Effect of raloxifene on disease activity and vascular biomarkers in patients with systemic lupus erythematosus: subgroup analysis of a double-blind randomized controlled trial.
Mok CC; Ying SK; Ma KM; Wong CK
Lupus; 2013 Dec; 22(14):1470-8. PubMed ID: 24113197
[TBL] [Abstract][Full Text] [Related]
19. Cortical thinning and progressive cortical porosity in female patients with systemic lupus erythematosus on long-term glucocorticoids: a 2-year case-control study.
Zhu TY; Griffith JF; Qin L; Hung VW; Fong TN; Au SK; Tang XL; Kun EW; Kwok AW; Leung PC; Li EK; Tam LS
Osteoporos Int; 2015 Jun; 26(6):1759-71. PubMed ID: 25736166
[TBL] [Abstract][Full Text] [Related]
20. Dehydroepiandrosterone for systemic lupus erythematosus.
Crosbie D; Black C; McIntyre L; Royle PL; Thomas S
Cochrane Database Syst Rev; 2007 Oct; 2007(4):CD005114. PubMed ID: 17943841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
